ViroPharma can trace its genesis to a series of meetings held by its five founders during the summer and fall of 1994, where the long-time colleagues and collaborators agreed upon a scientific strategy that would focus on the mechanisms that allow RNA viruses to reproduce.

CEO Claude Nash had worked at one time or another with all of his senior management group during his career in the pharmaceutical industry.